Results 11 to 20 of about 14,538,270 (379)
Enhanced Factor IX Activity following Administration of AAV5-R338L “Padua” Factor IX versus AAV5 WT Human Factor IX in NHPs [PDF]
Molecular Therapy: Methods & Clinical Development, 2019 Gene therapy for severe hemophilia B is advancing and offers sustained disease amelioration with a single treatment. We have reported the efficacy and safety of AMT-060, an investigational gene therapy comprising an adeno-associated virus serotype 5 ...
Elisabeth A. Spronck +10 more
doaj +5 more sources
Activation of Factor IX by Factor XIa - A Spectrophotometric Assay for Factor IX in Human Plasma [PDF]
Thrombosis and Haemostasis, 1982 SummaryThe activation of Factor IX by partially purified Factor XIa was followed by active site titration, gelelectrophoresis and by a spectrophotometric assay. The assay is based on the finding that the rate of Factor X activation in the presence of phospholipid and Ca2+ is linear in time and proportional to the amount of Factor IXa present and can be
H.C. Hemker +4 more
openaire +3 more sources
The B-team: Equal but different?
The Journal of Haemophilia Practice, 2021 As a person with haemophilia B, I have known there are differences between haemophilia A and haemophilia B and their respective treatment throughout my life – though I was shocked when I learnt about the impact inhibitors can have when it comes to ...
Pembroke Luke
doaj +1 more source
A Case of Heel Reconstruction with a Reverse Sural Artery Flap in a Hemophilia B Patient
Archives of Plastic Surgery, 2012 Hemophilia B is a rare blood coagulation disorder. Complications such as bleeding and hematoma can cause necrosis of flaps, wound disruption, and the disturbance of wound healing.
Byung Kwon Lee, Jeong Su Shim
doaj +1 more source
TH Open, 2022 In resource-rich countries, almost all severe hemophilia patients receive prophylactic replacement therapy with factor concentrates to prevent spontaneous bleeding in joints and muscles to decrease the development of arthropathy and risk of long-term ...
Tine M.H.J. Goedhart +13 more
doaj +1 more source
X-Ray Determination of the Variable Rate of Mass Accretion onto TW Hydrae [PDF]
, 2012 Diagnostics of electron temperature (T_e), electron density (n_e), and hydrogen column density (N_H) from the Chandra High Energy Transmission Grating spectrum of He-like Ne IX in TW Hydrae (TW Hya), in conjunction with a classical accretion model, allow
Brickhouse, N. S. +5 more
core +2 more sources
Factor IX and thrombosis [PDF]
British Journal of Haematology, 2001 No abstract available.
openaire +3 more sources
Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia [PDF]
, 2017 The most worrying complication of replacement therapy for severe hemophilia A and B is currently the occurrence of inhibitory alloantibodies against infused factor VIII and factor IX, respectively.
Franchini, Massimo +6 more
core +1 more source
Case Reports in Transplantation, 2020 Herein, we discuss a case of a 39-year-old male with hemophilia B, who developed end-stage liver disease secondary to nonalcoholic steatohepatitis, that underwent orthotopic liver transplantation (OLT) as a curative means for his liver disease and ...
Jesse E. Harris +3 more
doaj +1 more source